Last reviewed · How we verify
Neuropathic pain associated with spinal cord injury — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Lyrica | Pregabalin | Pfizer Inc. | Anticonvulsant, analgesic | alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels) | ||
| Neurontin | Gabapentin | Pfizer Inc. | Antiepileptic/Analgesic | α2δ subunit of voltage-activated calcium channels |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 2 drugs in Neuropathic pain associated with spinal cord injury
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Neuropathic pain associated with spinal cord injury:
- Neuropathic pain associated with spinal cord injury treatment updates — RSS
- Neuropathic pain associated with spinal cord injury treatment updates — Atom
- Neuropathic pain associated with spinal cord injury treatment updates — JSON
Cite this brief
Drug Landscape (2026). Neuropathic pain associated with spinal cord injury — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuropathic-pain-associated-with-spinal-cord-injury. Accessed 2026-06-10.
Related
- Neuropathic pain associated with spinal cord injury full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing